Patrys

(v2) Home

Get news and updates from Patrys delivered to your inbox.

Contact

Deoxymabs

Why invest?

AQS Platform

Management

Board

Company History

About

Prospectus

Corporate Governance

Market Data

Announcements

Annual Reports

Presentations

Investors

Home

Updates

Montserrat

Patrys Investor Hub

Accelerated development of a proprietary IV formulation of quetiapine, entering clinical trials. Targeting individuals suffering from delirium, a common, acute brain dysfunction characterized by confusion and agitation in postoperative, intensive care, and palliative care settings.

Early-stage development of a revolutionary and versatile antibody platform, deoxymabs, for cancer and inflammatory disease. Targeting NETosis which is involved in the development of cancer, and many inflammatory and autoimmune diseases.

Latest announcements